Manufacture of Asymmetric Hydrogenation Catalysts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacture of Asymmetric Hydrogenation Catalysts
Single-enantiomer drugs represent an increasingly large share of new chemical entities, leading to approaches in asymmetric synthesis.


Pharmaceutical Technology


Ian C. Lennon*, PhD, is a scientist and technology leader, Nicholas B. Johnson, PhD, is a business development and marketing manager, and Paul H. Moran, PhD, is a research specialist at Chirotech Technology Ltd., Dowpharma, Unit 162, Cambridge Science Park, Milton Road, Cambridge, UK, tel. + 44 (0) 1223.728037, fax +44 (0)1223.506701
.

*To whom all correspondence should be addressed.

References

1. W.S. Knowles, "Asymmetric Hydrogenations," Angew Chem. Int. Ed. 41 (12), 1998–2007 (2002).

2. R. Noyori, Asymmetric Catalysis in Organic Synthesis (John Wiley & Sons Inc, New York, 1994).

3. M.A. Schwindt et al., "Enantioselective Synthesis of a Key Intermediate in a New Process for Orlistat Using Asymmetric Hydrogenation and a Grignard Reagent Promoted Lactone Cyclization," Org. Process Res. Dev. 11 (3), 524–533 (2007).

4. M.J. Burk, "Modular Phospholane Ligands in Asymmetric Catalysis," Acc. Chem. Res. 33 (6), 363–372 (2000).

5. A. Togni et al., "A Novel Easily Accessible Chiral Ferrocenyldiphosphine for Highly Enantioselective Hydrogenation, Allylic Alkylation, and Hydroboration Reactions," J. Am. Chem. Soc. 116 (9), 4062–4066 (1994).

6. H.U. Blaser, "The Chiral Switch of (S)-Metolachlor: A Personal Account of an Industrial Odyssey in Asymmetric Catalysis," Adv. Synth. Catal. 344 (1), 17–31 (2002).

7. I.C. Lennon and C.J. Pilkington, "The Application of Asymmetric Hydrogenation for the Manufacture of Pharmaceutical Intermediates: The Need for Catalyst Diversity," Synthesis (11), 1639–1642 (2003).

8. W. Tang and X. Zhang, "New Chiral Phosphorus Ligands for Enantioselective Hydrogenation," Chem. Rev. 103 (8) 3029–3069 (2003).

9. T.Yamano et al., "Approach to the Stereoselective Synthesis of Melatonin Receptor Agonist Ramelteon via Asymmetric Hydrogenation," Tetrahedron: Asymmetry 17 (2), 184–190 (2002).

10. Y. Hsiao et al., "Highly Efficient Synthesis of β-Amino Acid Derivatives via Asymmetric Hydrogenation of Unprotected Enamines," J. Am. Chem. Soc. 126 (32), 9918–9919 (2004).

11. J.A.F. Boogers et al., "A Mixed-Ligand Approach Enables the Asymmetric Hydrogenation of an α-Isopropylcinnamic Acid en Route to the Renin Inhibitor Aliskiren," Org. Process Res. Dev. 11 (3), 585–591.

12. C. Cobley et al., "The Application of DuPHOS Rhodium(I) Catalysts for Commercial Scale Asymmetric Hydrogenation" in Asymmetric Catalysis on Industrial Scale, H.U. Blaser and E. Schmidt, Eds. (Wiley–VCH, Weinheim, Germany, 2004), p. 269–282.

13. M.J. Burk et al., "Practical Access to 2-Alkylsuccinates through Asymmetric Catalytic Hydrogenation of Stobbe-Derived Itaconates," Angew. Chem. Int. Ed., 37 (13–14), 1931–1933 (1998).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here